APP and Alzheimer disease: Other therapeutic approaches currently under study for AD are as follows: Caprydilene, which improves cytoplasmic energetic capacity [35,36]; nonsteroidal anti-inflammatory drugs (NSAIDs) such as Flurbiprofen, which inhibits APP cleavage secretases [37]; and valproic acid, which blocks microtubule dissociation and has a neuroprotective effect in AD [38] rosiglitazone, which increases insulin sensitivity and glucose utilization [39,40], among others (Table 1).